Logo image of ALDMS.PA

DIAGNOSTIC MEDICAL SYSTEMS (ALDMS.PA) Stock Fundamental Analysis

EPA:ALDMS - Euronext Paris - Matif - FR0012202497 - Common Stock - Currency: EUR

0.993  +0 (+0.4%)

Fundamental Rating

3

Taking everything into account, ALDMS scores 3 out of 10 in our fundamental rating. ALDMS was compared to 53 industry peers in the Health Care Equipment & Supplies industry. ALDMS has a bad profitability rating. Also its financial health evaluation is rather negative. ALDMS has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALDMS has reported negative net income.
ALDMS had a positive operating cash flow in the past year.
In the past 5 years ALDMS always reported negative net income.
In multiple years ALDMS reported negative operating cash flow during the last 5 years.
ALDMS.PA Yearly Net Income VS EBIT VS OCF VS FCFALDMS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M

1.2 Ratios

The Return On Assets of ALDMS (-5.34%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -22.44%, ALDMS is doing worse than 62.26% of the companies in the same industry.
Industry RankSector Rank
ROA -5.34%
ROE -22.44%
ROIC N/A
ROA(3y)-9.22%
ROA(5y)-9.28%
ROE(3y)-35.31%
ROE(5y)-31.48%
ROIC(3y)N/A
ROIC(5y)N/A
ALDMS.PA Yearly ROA, ROE, ROICALDMS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

Looking at the Gross Margin, with a value of 39.92%, ALDMS is doing worse than 69.81% of the companies in the same industry.
ALDMS's Gross Margin has improved in the last couple of years.
ALDMS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.05%
GM growth 5Y2.79%
ALDMS.PA Yearly Profit, Operating, Gross MarginsALDMS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

3

2. Health

2.1 Basic Checks

ALDMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALDMS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALDMS has been increased compared to 5 years ago.
The debt/assets ratio for ALDMS has been reduced compared to a year ago.
ALDMS.PA Yearly Shares OutstandingALDMS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ALDMS.PA Yearly Total Debt VS Total AssetsALDMS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

ALDMS has an Altman-Z score of 0.81. This is a bad value and indicates that ALDMS is not financially healthy and even has some risk of bankruptcy.
ALDMS has a Altman-Z score of 0.81. This is comparable to the rest of the industry: ALDMS outperforms 41.51% of its industry peers.
ALDMS has a debt to FCF ratio of 5.57. This is a neutral value as ALDMS would need 5.57 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.57, ALDMS is in the better half of the industry, outperforming 66.04% of the companies in the same industry.
ALDMS has a Debt/Equity ratio of 0.90. This is a neutral value indicating ALDMS is somewhat dependend on debt financing.
ALDMS has a worse Debt to Equity ratio (0.90) than 73.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 5.57
Altman-Z 0.81
ROIC/WACCN/A
WACC6.61%
ALDMS.PA Yearly LT Debt VS Equity VS FCFALDMS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M

2.3 Liquidity

ALDMS has a Current Ratio of 1.29. This is a normal value and indicates that ALDMS is financially healthy and should not expect problems in meeting its short term obligations.
ALDMS has a Current ratio of 1.29. This is comparable to the rest of the industry: ALDMS outperforms 45.28% of its industry peers.
A Quick Ratio of 0.67 indicates that ALDMS may have some problems paying its short term obligations.
ALDMS has a Quick ratio of 0.67. This is in the lower half of the industry: ALDMS underperforms 62.26% of its industry peers.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 0.67
ALDMS.PA Yearly Current Assets VS Current LiabilitesALDMS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.00% over the past year.
The Revenue has grown by 9.29% in the past year. This is quite good.
ALDMS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.24% yearly.
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87%
Revenue 1Y (TTM)9.29%
Revenue growth 3Y7.62%
Revenue growth 5Y8.24%
Sales Q2Q%8.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
Based on estimates for the next years, ALDMS will show a quite strong growth in Revenue. The Revenue will grow by 11.55% on average per year.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year19.4%
Revenue Next 2Y13.86%
Revenue Next 3Y11.55%
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALDMS.PA Yearly Revenue VS EstimatesALDMS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
ALDMS.PA Yearly EPS VS EstimatesALDMS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2023 2025 2026 2027 0 0.05 -0.05 0.1 -0.1 -0.15

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ALDMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 9.64, which indicates a very decent valuation of ALDMS.
Based on the Price/Forward Earnings ratio, ALDMS is valued cheaply inside the industry as 88.68% of the companies are valued more expensively.
ALDMS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 20.44.
Industry RankSector Rank
PE N/A
Fwd PE 9.64
ALDMS.PA Price Earnings VS Forward Price EarningsALDMS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ALDMS is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 4.99
EV/EBITDA N/A
ALDMS.PA Per share dataALDMS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALDMS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DIAGNOSTIC MEDICAL SYSTEMS

EPA:ALDMS (5/9/2025, 7:00:00 PM)

0.993

+0 (+0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.25%
Ins Owner ChangeN/A
Market Cap17.97M
Analysts86.67
Price Target1.84 (85.3%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)4.28%
Revenue NY rev (3m)4.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.64
P/S 0.39
P/FCF 4.99
P/OCF 4.99
P/B 1.4
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)0.1
Fwd EY10.37%
FCF(TTM)0.2
FCFY20.04%
OCF(TTM)0.2
OCFY20.04%
SpS2.55
BVpS0.71
TBVpS-0.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.34%
ROE -22.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.92%
FCFM 7.82%
ROA(3y)-9.22%
ROA(5y)-9.28%
ROE(3y)-35.31%
ROE(5y)-31.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.05%
GM growth 5Y2.79%
F-Score6
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 5.57
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 0.67
Altman-Z 0.81
F-Score6
WACC6.61%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.29%
Revenue growth 3Y7.62%
Revenue growth 5Y8.24%
Sales Q2Q%8.7%
Revenue Next Year19.4%
Revenue Next 2Y13.86%
Revenue Next 3Y11.55%
Revenue Next 5YN/A
EBIT growth 1Y35.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1025%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y318.91%
FCF growth 3YN/A
FCF growth 5Y58.15%
OCF growth 1Y318.91%
OCF growth 3YN/A
OCF growth 5Y58.15%